Alkermes appoints Nancy S. Lurker to Board of Directors, increasing size to 11

Alkermes plc.

Board expanded to 11 directors; Nancy S. Lurker elected effective March 5, 2024, term expiring at 2024 annual meeting.
Lurker brings decades of pharmaceutical/biotech leadership and commercial expertise; CEO highlights alignment with growth strategy.
She will receive standard new director equity grant and annual cash retainer; equity grants in April 2024 subject to re-election forfeiture.
Lurker not a party to any related-party transactions since Jan 1, 2023.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nancy S. Lurker

Director

ALKS · Alkermes plc.

Effective: 2024-03-05
Filed: March 7, 2024, 6:59 PM ET

Effective March 5, 2024, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board to eleven (11) directors and elected Nancy S. Lurker to the Board, with an initial term expiring at the Company’s 2024 annual general meeting of shareholders (the “2024 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy S. Lurker was elected as Director at Alkermes plc..

Action: elected
Role: Director

Exact text from the filing

Effective March 5, 2024, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board to eleven (11) directors and elected Nancy S. Lurker to the Board, with an initial term expiring at the Company’s 2024 annual general meeting of shareholders (the “2024 Annual Meeting”).

View on SEC.gov

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0000950170-24-027585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.